Argenx (ARGX)
(Delayed Data from NSDQ)
$371.02 USD
+8.86 (2.45%)
Updated May 31, 2024 04:00 PM ET
After-Market: $371.31 +0.29 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
argenex SE [ARGX]
Reports for Purchase
Showing records 181 - 200 ( 279 total )
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
ADAPT To a New Bar for MG Therapies - Efgartigimod a Winner
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Q1 Financials; Topline Pivotal ADAPT Readout Around the Corner in Mid-2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Far From Any Road: ADAPT-ing to the Present, Looking to the Near Future
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Biotechnology- From Underneath the Rubble Sing a Rebel Song
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: argenex SE
Industry: Medical - Biomedical and Genetics
From Underneath The Rubble Sing a Rebel Song
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
KOL Perspectives on FcRn''s for the Treatment of Myasthenia Gravis
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Details Emerge on Pivotal Ph 3 ADAPT Study for Myasthenia Gravis
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Positive Pemphigus Update + Accelerated ADAPT Readout
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Breakfast of Champions: Who''s Going to Win the MG and FcRn Races?
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
ASH 2019: Hangover: Covered Companies Roundup
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D